Related Experiment Video
Updated: Dec 8, 2025
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among
Özlem Uzunkaya Ethemoğlu1, Nalan Kayrak2, Bilge Bılgıç3
1Department of Neurology, Harran University School of Medicine, Şanlıurfa, Turkey.
Introduction:
The overproduction of the efflux transporters in the blood-brain barrier is considered to play a role in the development of drug resistance in mesial temporal lobe epilepsy (MTLE) patients. The aim of the present study was to investigate the relationship of clinical features of patients with MTLE accompanied by hippocampal sclerosis (HS) and the p-glycoprotein (p-gp) expression and neuronal loss in the hippocampus.
Methods:
This study included a total of 33 patients who underwent selective amygdala-hippocampectomy operation. A detailed medical history of each patient, including age, side of HS, sex, age of habitual seizure onset, duration of habitual seizures, type and age of initial precipitating injury, presence and duration of latent period, presence and duration of silent period, monthly seizure frequency within 1 year prior to operation, mean age at the time of operation was evaluated retrospectively.
Results:
The p-gp expression was significantly higher in the patient group with a seizure frequency of more than 15 days per month and a disease duration of more than 20 years. There was no significant difference between the p-gp expression and the clinical features of the MTLE-HS patients.
Conclusion:
These results suggest that p-gp expression is affected by disease duration and seizure frequency rather than a patient's clinical and pathological properties. In patients with HS-MTLE, potential use of the p-gp inhibitors as additional therapy and developing novel drugs not carried by multidrug carriers expressed in blood-brain barrier should be regarded as the new treatment targets.
Insights
P-glycoprotein (p-gp) expression in mesial temporal lobe epilepsy (MTLE) with hippocampal sclerosis (HS) correlates with disease duration and seizure frequency, not other clinical features. This suggests new therapeutic targets for drug resistance in MTLE patients.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Overproduction of blood-brain barrier efflux transporters, like p-glycoprotein (p-gp), is implicated in drug resistance in mesial temporal lobe epilepsy (MTLE).
- Understanding the relationship between clinical features and p-gp expression in MTLE patients with hippocampal sclerosis (HS) is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the association between clinical characteristics of MTLE patients with HS and their hippocampal p-glycoprotein (p-gp) expression and neuronal loss.
- To identify factors influencing p-gp expression in the context of MTLE-HS.
Main Methods:
- Retrospective analysis of 33 MTLE patients who underwent selective amygdala-hippocampectomy.
- Detailed evaluation of medical history, including seizure onset, duration, frequency, and patient demographics.
Main Results:
- P-glycoprotein (p-gp) expression was significantly elevated in patients with over 15 seizure days/month and disease duration exceeding 20 years.
- No significant correlation was found between p-gp expression and other evaluated clinical features in MTLE-HS patients.
Conclusions:
- P-glycoprotein (p-gp) expression in HS-MTLE is primarily influenced by disease duration and seizure frequency.
- P-gp inhibitors and novel drugs not reliant on multidrug transporters represent potential therapeutic strategies for drug-resistant MTLE.
